Anti-HER2-Tra-hIgG4 (S228P)

Monoclonal human IgG4 (S228P) antibody against HER2

Anti-HER2-Tra-hIgG4 (S228P) features the constant region of the human IgG4 (S228P) isotype and the variable region of trastuzumab. Trastuzumab is a humanized IgG1 monoclonal antibody that targets the HER2 receptor (human epidermal growth factor receptor 2 also known as HER2/neu) that is found on the cell membrane of epithelial cells. HER2 plays an important role in normal cell growth and differentiation [1]. However, in certain types of cancers, particularly in breast and ovarian cancers, HER2 is over-expressed and causes uncontrollable cell proliferation. Binding of trastuzumab to HER2 results in cell death through different mechanisms including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2, 3]. Trastuzumab has been approved by the FDA for the treatment of breast cancer.
Anti-HER2-Tra-hIgG4 (S228P) contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules.
Anti-HER2-Tra-hIgG4 (S228P) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


Specificity: Targets cells expressing HER2
Clonality: Monoclonal antibody
Isotype: Human IgG4 (S228P)
Source: CHO cells
Purity: Purified by affinity chromatography with protein G


100 µg purified anti-HER2-Tra-hIgG4 (S228P) antibody, provided azide-free and lyophilized


- Binding of Anti-HER2-Tra-hIgG4 (S228P) to HER2 has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.


1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell- mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.


Recent articles using InvivoGen Anti-HER2-Tra-hIgG4 (S228P)


Anti-HER2-Tra-hIgG4 (S228P)

Description HER2 (trastuzumab) antibody - Human IgG4 (S228P)
Cat. Codeher2tra-mab14
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".